Cytarabine/daunorubicin liposomal

Drug Profile

Cytarabine/daunorubicin liposomal

Alternative Names: CPX-351; Cytarabine:daunorubicin - Jazz Pharmaceuticals; Cytarabine:daunorubicin liposome injection - Jazz Pharmaceuticals; Daunorubicin/cytarabine; NS 87; VYXEOS

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celator Pharmaceuticals
  • Developer Cardiff University; Celator Pharmaceuticals; Cincinnati Childrens Hospital Medical Center; Fred Hutchinson Cancer Research Center; Jazz Pharmaceuticals plc; National Cancer Institute (USA); Stanford University; The Leukemia & Lymphoma Society; University of Texas M. D. Anderson Cancer Center
  • Class Anthracyclines; Antineoplastics; Arabinonucleosides; Cytostatic antibiotics; Daunorubicins; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA intercalators; DNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase III Myelodysplastic syndromes
  • Phase II Acute lymphoblastic leukaemia
  • No development reported Lymphoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Myelodysplastic-syndromes(First-line therapy) in USA (IV, Liposomal)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-lymphoblastic-leukaemia(In adolescents, In children, In infants, Second-line therapy or greater, In adults) in USA (IV, Liposomal)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(In adolescents, In children, In infants, Second-line therapy or greater, In adults) in USA (IV, Liposomal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top